|
British Columbia
(州或其他管轄範圍
成立公司或組織) |
| |
2834
(主要標準工業
分類代碼號) |
| |
N/A
(I.R.S. Employer
Identification No.) |
|
|
Copies to:
|
| |||||||||
|
Thomas M. Rose
Troutman Pepper Hamilton Sanders LLP 401 9th Street, N.W. Suite 1000 Washington, DC 20004 (202) 274-2950 |
| |
Rick Pawluk
Fasken Martineau DuMoulin LLP 350 7th Avenue SW, Suite 3400 Calgary AB T2P 3N9 Canada (587)-233-4063 |
| |
Ivan Blumenthal
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 666 Third Avenue New York, NY 10017 (212) 935-3000 |
| |
Scott Reeves
Ariane Young TingleMerrett LLP 639 5 Ave SW #1250 Calgary, AB T2P 0M9 Canada (403) 571-8000 |
|
|
About This Prospectus
|
| | | | 1 | | |
|
Prospectus Summary
|
| | | | 2 | | |
|
Risk Factors
|
| | | | 13 | | |
|
有關前瞻性陳述的告誡説明
|
| | | | 63 | | |
|
財務信息展示
|
| | | | 64 | | |
|
Exchange Rate Data
|
| | | | 65 | | |
|
市場、行業等數據
|
| | | | 66 | | |
|
Use of Proceeds
|
| | | | 67 | | |
|
Dividend Policy
|
| | | | 68 | | |
|
Capitalization
|
| | | | 69 | | |
|
Dilution
|
| | | | 71 | | |
|
財務報表與管理層對財務狀況和經營成果的討論與分析
|
| | | | 73 | | |
|
Business
|
| | | | 74 | | |
|
Management
|
| | | | 106 | | |
|
高管和董事薪酬
|
| | | | 115 | | |
|
某些關係和關聯方交易
|
| | | | 121 | | |
|
主要股東
|
| | | | 123 | | |
|
股本説明
|
| | | | 125 | | |
|
有資格未來出售的股票
|
| | | | 134 | | |
|
Taxation
|
| | | | 135 | | |
|
Underwriting
|
| | | | 150 | | |
|
與此產品相關的費用
|
| | | | 157 | | |
|
Legal Matters
|
| | | | 158 | | |
|
Experts
|
| | | | 158 | | |
|
披露委員會對賠償的立場
|
| | | | 158 | | |
|
在哪裏可以找到更多信息
|
| | | | 158 | | |
| | |
Year Ended
|
| |||||||||
| | |
December 31,
2021 |
| |
December 31,
2020 |
| ||||||
| | |
$
|
| |
$
|
| ||||||
Expenses | | | | | | | | | | | | | |
Amortization
|
| | | | 17,882 | | | | | | 20,439 | | |
Consulting
|
| | | | 724,272 | | | | | | 102,880 | | |
Directors’ fees
|
| | | | 62,200 | | | | | | — | | |
一般和行政
|
| | | | 176,099 | | | | | | 9,516 | | |
Investor relations
|
| | | | 518,615 | | | | | | 241,177 | | |
Listing fees
|
| | | | 236,801 | | | | | | 52,138 | | |
Professional fees
|
| | | | 272,943 | | | | | | 162,580 | | |
Research and development
|
| | | | 853,124 | | | | | | 277,455 | | |
Share-based payments
|
| | | | 499,158 | | | | | | 293,443 | | |
Travel
|
| | | | 2,339 | | | | | | 8,460 | | |
Wages and benefits
|
| | | | 286,090 | | | | | | 227,905 | | |
Loss before other items
|
| | | | (3,649,523) | | | | | | (1,395,993) | | |
Accretion
|
| | | | — | | | | | | (846) | | |
衍生權證債務的交易成本
|
| | | | (1,623,680) | | | | | | — | | |
衍生權證負債的公允價值調整
|
| | | | 3,299,768 | | | | | | — | | |
Foreign exchange gain (loss)
|
| | | | 326,751 | | | | | | 2,961 | | |
無形資產減值準備
|
| | | | — | | | | | | (64,562) | | |
利息和其他費用
|
| | | | (5,598) | | | | | | (12,666) | | |
Forgiveness of debt
|
| | | | — | | | | | | 91,014 | | |
專利取得撥備的收回
|
| | | | — | | | | | | 95,490 | | |
本年度淨虧損和綜合虧損
|
| | | | (1,652,282) | | | | | | (1,284,602) | | |
每股普通股基本和攤薄虧損
|
| | | | (0.17) | | | | | | (0.19) | | |
已發行普通股加權平均數 | | | | | | | | | | | | | |
Basic and diluted
|
| | | | 9,847,641 | | | | | | 6,664,025 | | |
Year Ended
|
| |
Average
|
| |||
December 31, 2021
|
| | | | 0.7978 | | |
December 31, 2020
|
| | | | 0.7454 | | |
December 31, 2019
|
| | | | 0.7536 | | |
| | |
As of June 30, 2022
|
| ||||||
| | |
Actual
|
| |
Pro forma as
adjusted(1) |
| |||
| | |
(千為單位,共享數據除外)
|
| ||||||
Cash
|
| | | $ | 13,420 | | | | | |
Equity
|
| | | | | | | | | |
Share capital
|
| | | $ | 20,009 | | | | | |
普通股,無限授權股份,無面值;12,989,987股已發行和流通股,實際; 已發行和已流通股,調整後形式
|
| | | | | | | | | |
股份支付、權證準備金和其他
|
| | | $ | 6,898 | | | | | |
發行股票的義務
|
| | | $ | 32 | | | | | |
Deficit
|
| | | $ | (14,695) | | | | | |
Total Equity
|
| | | $ | 12,244 | | | | | |
Total Capitalization
|
| | | $ | | | | | |
|
假設單位發行價(1)
|
| | | $ | | | |
|
截至2022年6月30日的每股有形賬面淨值
|
| | | $ | 0.92 | | |
|
可歸因於投資者的每股有形賬面淨值增加
|
| | | $ | | | |
|
上市後每股有形賬面淨值
|
| | | $ | | | |
|
對新投資者的每股攤薄
|
| | | $ | | | |
Patent
Family No. |
| |
Patent Family Name
|
| |
XRx-101
|
| |
XRx-008
|
| |
XRx-225
|
| |
其他潛在候選人
|
|
1 | | | 黃嘌呤氧化酶抑制劑配方專利-腎臟、心血管、神經 | | |
X
|
| |
X
|
| |
X
|
| | 其他適應症,如罕見的腎臟疾病、心血管和神經疾病 | |
2 | | | 病毒、冠狀病毒、敗血癥健康後果 - 病毒引起的急性器官、腎臟損傷 | | |
X
|
| | | | | | | | 一般適用於病毒感染,包括對呼吸道和健康的影響。 | |
3 | | | 加強抗病毒治療的方法 - 病毒和細菌感染 | | |
X
|
| | | | | | | | 一般適用於病毒感染,包括對呼吸道和健康的影響 | |
4 | | | 治療和預防胰島素抵抗的成分和方法 | | | | | | | | |
X
|
| | | |
5 | | | 代謝綜合徵降尿酸藥(治療糖尿病腎病) | | | | | | | | |
X
|
| | | |
6 | | | 腎臟疾病的診斷、治療和預防的成分和方法 | | |
X
|
| | | | |
X
|
| | | |
Name
|
| |
Residence
|
| |
Age
|
| |
Position(s)
|
|
執行主任 | | | | | | | | | | |
Allen Warren Davidoff
|
| | Alberta, Canada | | |
61
|
| |
董事首席執行官總裁
|
|
Amar Keshri | | | Alberta, Canada | | |
43
|
| | 首席財務官 | |
Stephen Haworth | | |
美國賓夕法尼亞州
|
| |
71
|
| | 首席醫療官 | |
Directors | | | | | | | | | | |
William Farley | | | New York, United States | | |
67
|
| | Director | |
Anthony Giovinazzo | | | Ontario, Canada | | |
66
|
| | Director | |
Ian Klassen(1) | | | 加拿大不列顛哥倫比亞省 | | |
56
|
| | Director | |
Jacqueline Le Saux(1) | | | Ontario, Canada | | |
69
|
| | Director | |
Raymond Pratt | | | 美國馬裏蘭州 | | |
71
|
| | Director | |
Paul Van Damme(1) | | | Ontario, Canada | | |
72
|
| | Director | |
| | |
December, 31
2021 ($) |
| |
December, 31
2020 ($) |
| |
December, 31
2019 ($) |
| |
December 31,
2018 ($) |
| ||||||||||||
Audit Fees(1)
|
| | | $ | 49,000 | | | | | $ | 18,750 | | | | | $ | 13,500 | | | | | $ | 13,500 | | |
Audit-Related Fees(2)
|
| | | | 397 | | | | | | — | | | | | | — | | | | | | — | | |
Tax Fees(3)
|
| | | | 2,500 | | | | | | — | | | | | | 3,000 | | | | | | 3,000 | | |
All Other Fees(4)
|
| | | | 16,000 | | | | | | — | | | | | | — | | | | | | 950 | | |
Total Fees Paid
|
| | | $ | 67,897 | | | | | $ | 18,750 | | | | | $ | 25,500 | | | | | $ | 17,450 | | |
| | |
不包括補償證券的報酬表
|
| |||||||||||||||||||||||||||||||||||||||
Name and Position
|
| |
Year
|
| |
Salary,
Consulting Fee, Retainer or Commission ($) |
| |
Bonus
($) |
| |
Committee
or Meeting Fees ($) |
| |
Value of
Stock Option ($) |
| |
Value of
All Other Compensation ($) |
| |
Total
Compensation ($) |
| |||||||||||||||||||||
Allen Davidoff
首席執行官 |
| | | | 2021 | | | | | | 221,840 | | | | | | 25,000 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 246,840 | | |
| | | 2020 | | | | | | 196,097 | | | | | | 無 | | | | | | 無 | | | | | | 63,072 | | | | | | 無 | | | | | | 259,169 | | | ||
| | | 2019 | | | | | | 192,000 | | | | | | 無 | | | | | | 無 | | | | | | 17,137 | | | | | | 無 | | | | | | 209,137 | | | ||
Amar Keshri(1)
首席財務官 |
| | | | 2021 | | | | | | 85,000 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 17,446 | | | | | | 無 | | | | | | 102,446 | | |
| | | 2020 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | ||
| | | 2019 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | ||
James Fairbairn(1)
Former Chief Financial Officer |
| | | | 2021 | | | | | | 58,500 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 58,500 | | |
| | | 2020 | | | | | | 30,000 | | | | | | 無 | | | | | | 無 | | | | | | 15,635 | | | | | | 無 | | | | | | 45,635 | | | ||
| | | 2018 | | | | | | 30,000 | | | | | | 無 | | | | | | 無 | | | | | | 12,510 | | | | | | 無 | | | | | | 42,510 | | | ||
William Farley(2)
Director |
| | | | 2021 | | | | | | 6,000 | | | | | | 無 | | | | | | 1,200 | | | | | | 55,963 | | | | | | 不適用 | | | | | | 63,163 | | |
| | | 2020 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | ||
| | | 2019 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | |
| | |
不包括補償證券的報酬表
|
| |||||||||||||||||||||||||||||||||||||||
Name and Position
|
| |
Year
|
| |
Salary,
Consulting Fee, Retainer or Commission ($) |
| |
Bonus
($) |
| |
Committee
or Meeting Fees ($) |
| |
Value of
Stock Option ($) |
| |
Value of
All Other Compensation ($) |
| |
Total
Compensation ($) |
| |||||||||||||||||||||
Ian Klassen(3)
Director |
| | | | 2021 | | | | | | 6,000 | | | | | | 無 | | | | | | 2,200 | | | | | | 86,728 | | | | | | 無 | | | | | | 94,928 | | |
| | | 2020 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 30,988 | | | | | | 無 | | | | | | 30,988 | | | ||
| | | 2019 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | ||
Jacqueline Le Saux(2)
Director |
| | | | 2021 | | | | | | 6,000 | | | | | | 無 | | | | | | 2,300 | | | | | | 54,463 | | | | | | 不適用 | | | | | | 62,763 | | |
| | | 2020 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | ||
| | | 2019 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | ||
Raymond Pratt(4)
Director |
| | | | 2021 | | | | | | 無 | | | | | | 無 | | | | | | 300 | | | | | | 57,922 | | | | | | 不適用 | | | | | | 58,222 | | |
| | | 2020 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | ||
| | | 2019 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | | | | 不適用 | | | ||
Bruce Rowlands(5)
Former Director |
| | | | 2021 | | | | | | 40,950 | | | | | | 無 | | | | | | 2,600 | | | | | | 無 | | | | | | 無 | | | | | | 43,550 | | |
| | | 2020 | | | | | | 36,000 | | | | | | 無 | | | | | | 無 | | | | | | 41,348 | | | | | | 無 | | | | | | 77,348 | | | ||
| | | 2019 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | ||
Paul Van Damme
Director |
| | | | 2021 | | | | | | 6,000 | | | | | | 無 | | | | | | 3,600 | | | | | | 41,841 | | | | | | 無 | | | | | | 51,441 | | |
| | | 2020 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 33,387 | | | | | | 無 | | | | | | 33,387 | | | ||
| | | 2019 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | ||
Allan Williams(6)
Former Director |
| | | | 2021 | | | | | | 20,000 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 20,000 | | |
| | | 2020 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 33,387 | | | | | | 無 | | | | | | 33,387 | | | ||
| | | 2019 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | | | | | 無 | | |
| | |
補償證券
|
| ||||||||||||||||||
Name and Position
|
| |
Type of
Compensation Security |
| |
Number of
Compensation Securities, Number of Underlying Securities and Percentage of Class(1) |
| |
Date of Issue
or Grant |
| |
Issue,
Conver-sion or Exercise Price ($)(1) |
| |
Closing
Price of Security or Underlying Security on Date of Grant ($)(1) |
| |
Closing
Price of Security or Underlying Security at Year End ($) |
| |
Expiry Date
|
|
Allen Davidoff(2)
首席執行官 |
| |
N/A
|
| |
Nil
|
| |
N/A
|
| |
N/A
|
| |
N/A
|
| |
N/A
|
| |
N/A
|
|
Amar Keshri(3)
首席財務官 |
| |
Stock Option
|
| |
21,294
|
| |
Jul 14, 2021
|
| |
$2.41
|
| |
$2.41
|
| | | | |
Jul 14, 2026
|
|
| | | |
3.5%
|
| | | | | | ||||||||||||
James Fairbairn
前首席財務官 |
| |
N/A
|
| |
Nil
|
| |
N/A
|
| |
N/A
|
| |
N/A
|
| |
N/A
|
| |
N/A
|
|
William Farley(4)
Director |
| |
Stock Option
|
| |
21,294
|
| |
May 12, 2021
|
| |
$1.88
|
| |
$1.88
|
| |
$2.50
|
| |
May 12, 2026
|
|
| | | |
13,706
|
| |
Dec 21, 2021
|
| |
$2.54
|
| |
$2.54
|
| | | | |
Dec 21, 2026
|
| ||
| | | |
5.8%
|
| | | | | |
| | |
補償證券
|
| ||||||||||||||||||
Name and Position
|
| |
Type of
Compensation Security |
| |
Number of
Compensation Securities, Number of Underlying Securities and Percentage of Class(1) |
| |
Date of Issue
or Grant |
| |
Issue,
Conver-sion or Exercise Price ($)(1) |
| |
Closing
Price of Security or Underlying Security on Date of Grant ($)(1) |
| |
Closing
Price of Security or Underlying Security at Year End ($) |
| |
Expiry Date
|
|
Ian Klassen(5)
Director |
| |
Stock Option
|
| |
29,812
|
| |
Jan 11, 2021
|
| |
$3.29
|
| |
$3.29
|
| |
$2.50
|
| |
Jan 11, 2026
|
|
| | | |
7,412
|
| |
Dec 21, 2021
|
| |
$2.54
|
| |
$2.54
|
| | | | |
Dec 21, 2026
|
| ||
| | | |
6.1%
|
| | | | | | ||||||||||||
Jacqueline Le Saux(6)
Director |
| |
Stock Option
|
| |
21,294
|
| |
Jun 16, 2021
|
| |
$1.76
|
| |
$1.76
|
| |
$2.50
|
| |
Jun 16, 2026
|
|
| | | |
13,706
|
| |
Dec 21, 2021
|
| |
$2.54
|
| |
$2.54
|
| | | | |
Dec 21, 2026
|
| ||
| | | |
5.8%
|
| | | | | | ||||||||||||
Raymond Pratt(7)
Director |
| |
Stock Option
|
| |
30,000
|
| |
Dec 21, 2021
|
| |
$2.54
|
| |
$2.54
|
| |
$2.50
|
| | | |
| | | |
4.9%
|
| | | | | | ||||||||||||
Bruce Rowlands
Former Director |
| |
N/A
|
| |
Nil
|
| |
N/A
|
| |
N/A
|
| |
N/A
|
| |
N/A
|
| |
N/A
|
|
Paul Van Damme(8)
Director |
| |
Stock Option
|
| |
21,671
|
| |
Dec 21, 2021
|
| |
$2.54
|
| |
$2.54
|
| |
$2.50
|
| |
Dec 21, 2026
|
|
| | | |
3.6%
|
| | | | | | ||||||||||||
Allan Williams
Former Director |
| |
N/A
|
| |
Nil
|
| |
N/A
|
| |
N/A
|
| |
N/A
|
| |
N/A
|
| |
N/A
|
|
姓名和主要職務
|
| |
Event
|
| |
Severance
($)(1) |
| |
Options
($)(2) |
| |
Other
Payments ($) |
| |
Total
($) |
| ||||||||||||
Allen Davidoff,
首席執行官 |
| |
被公司終止
|
| | | | 389,595 | | | | | | | | | | | | — | | | | | | — | | |
| Change of Control | | | | | 389,595 | | | | | | | | | | | | — | | | | | | — | | | ||
Amar Keshri,
首席財務官 |
| |
被公司終止
|
| | | | 96,000 | | | | | | — | | | | | | — | | | | | | — | | |
| Change of Control | | | | | 192,000 | | | | | | — | | | | | | — | | | | | | — | | |
Plan Category
|
| |
Number of Securities
to be Issued upon Exercise of Outstanding Options, Warrants and Rights (#) |
| |
Weighted-average
Exercise Price of Outstanding Options, Warrants and Rights ($) |
| |
Number of Securities
remaining available for Future Issuance under Equity Compensation Plans (#) |
| |||||||||
證券持有人批准的股權補償計劃(1)
|
| | | | 593,291 | | | | | | 3.29 | | | | | | 705,678 | | |
股權補償計劃未經證券持有人批准
|
| | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | | 593,291 | | | | | | 3.29 | | | | | | 705,678 | | |
受益人姓名和地址
|
| |
Shares Beneficially
Owned |
| |
Percentage of Shares
Beneficially Owned |
| ||||||
5%及更大股東: | | | | | | | | | | | | | |
盛行合作伙伴關係有限責任公司(1)
|
| | | | 977,318 | | | | | | 7.5% | | |
董事和指定高管: | | | | | | | | | | | | | |
Davidoff, Allen(2)
|
| | | | 526,309 | | | | | | 4.0% | | |
Farley, William(3)
|
| | | | 65,000 | | | | | | *% | | |
Giovinazzo, Anthony(4)
|
| | | | 150,000 | | | | | | 1.1% | | |
Haworth, Stephen(5)
|
| | | | 10,053 | | | | | | *% | | |
Keshri, Amar(6)
|
| | | | 19,003 | | | | | | *% | | |
Klassen, Ian(7)
|
| | | | 122,759 | | | | | | *% | | |
Le Saux, Jacqueline(8)
|
| | | | 65,000 | | | | | | *% | | |
May, Charlotte(9)
|
| | | | 25,598 | | | | | | *% | | |
Pratt, Raymond(10)
|
| | | | 60,000 | | | | | | *% | | |
Van Damme, Paul(11)
|
| | | | 153,993 | | | | | | 1.2% | | |
全體高管和董事(10人)
|
| | | | 1,172,117 | | | | | | 9.02% | | |
Category
|
| |
Number of
Options to Acquire Common Shares |
| |
Exercise
Price ($)(1) |
| |
Expiration Date
|
| |||
我們所有的管理人員和所有的
of Our Directors, as a Group (10 in total) |
| | | | 807,399 | | | |
$1.60 to 5.87
|
| |
From March 19, 2023 to January 11, 2026
|
|
Date of Issuance
|
| |
Type of
Security |
| |
Number of
Securities Issued |
| |
Issuance/
行權價格 根據安全標準 ($) |
| |||
July 14, 2021
|
| | Options | | | | | 63,882 | | | |
2.41
|
|
October 15, 2021
|
| | Shares | | | | | 2,906,000 | | | |
5.11 (US$4.13)
|
|
October 15, 2021
|
| | Warrants | | | | | 2,906,000 | | | |
5.90 (US$4.77)
|
|
December 21, 2021
|
| | Options | | | | | 86,496 | | | |
2.54
|
|
January 12, 2022
|
| | Options | | | | | 127,500 | | | |
2.54
|
|
June 6, 2022
|
| | Options | | | | | 394,822 | | | |
1.60
|
|
Underwriter
|
| |
Number of
Common Share Units |
| |
Number of
Pre-Funded Warrant Units |
| |
Total
|
| |||||||||
A.G.P./聯盟全球合作伙伴
|
| | | | | | | | | | | | | | | | |||
Total
|
| | | | | | | | | | | | | | | | | | |
| | |
Per
Common Share Unit |
| |
Per Pre-
Funded Warrant Unit |
| |
Total
Without Over- Allotment |
| |
Total With
Over- Allotment |
|
Public offering price
|
| | | | | | | | | | | | |
承保折扣和佣金(7.0%)
|
| | | | | | | | | | | | |
扣除費用前的收益給我們。
|
| | | | | | | | | | | | |
Itemized expense
|
| |
Amount
|
|
SEC registration fee
|
| | | |
Nasdaq listing fee
|
| | | |
FINRA filing fee
|
| | | |
印刷費和雕刻費
|
| | | |
轉會代理費和註冊費
|
| | | |
Legal fees and expenses
|
| | | |
會計費和費用
|
| | | |
Total
|
| | | |
|
Exhibit
Number |
| |
Description
|
|
| 1.1** | | | 承保協議格式 | |
| 3.1 | | | 公司章程及章程公告(參考公司於2021年5月26日提交的F-1表格註冊説明書草案附件3.1) | |
| 4.1 | | | 普通股證書樣本(參考公司2022年5月3日提交的20-F表格年度報告附件2.1併入) | |
| 4.2** | | | Form of Warrant | |
| 4.3** | | | 預付資金授權書表格 | |
| 4.4** | | | 賠償授權書表格 | |
| 4.4 | | | 私募認股權證表格(參考本公司於2021年9月16日提交的F-1表格註冊説明書第1號修正案附件4.4)。 | |
| 4.5 | | | 首次公開發行普通股認購認股權證表格(參照本公司於2021年9月16日提交的F-1表格登記説明書第1號修正案附件4.1併入)。 | |
| 4.6 | | | 首次公開招股賠償認股權證表格(參考本公司於2021年9月16日提交的F-1表格註冊説明書第1號修正案附件4.4)。 | |
| 5.1** | | | 對Fasken Martineau Dumoulin LLP的看法 | |
| 5.2** | | | Troutman Pepper Hamilton Sanders LLP的意見 | |
| 10.1% | | | 該公司與位於西奈山的伊坎醫學院之間簽訂的研究人員發起的臨牀試驗協議,日期為2020年8月3日(通過參考2021年5月26日提交的公司F-1表格註冊聲明草案的附件10.1合併) | |
| 10.2# | | | 公司與Allen Davidoff簽訂的僱傭協議,日期為2021年8月1日(參考公司於2021年9月16日提交的F-1表格註冊説明書第1號修正案附件10.2) | |
| 10.3 | | | 本公司與加拿大CATO Research Inc.簽訂的主服務協議,日期為2017年7月20日(參照本公司於2021年5月26日提交的F-1表格註冊聲明草案附件10.3合併) | |
| 10.4#% | | | 本公司與David Sans簽訂的諮詢協議,日期為2021年2月1日(參考本公司於2021年5月26日提交的F-1表格註冊説明書草稿附件10.4) | |
| 10.5# | | | 公司與1282803安大略公司簽訂的諮詢協議,日期為2021年3月1日(參考公司於2021年10月4日提交的F-1表格註冊説明書修正案第2號附件10.5) | |
| 10.6% | | | 本公司與Pvail InfoWorks,Inc.之間簽訂的總服務和技術協議,日期為2019年2月25日(通過參考2021年5月26日提交的公司F-1表格註冊聲明草案的附件10.6合併) | |
| 10.7% | | | 《主服務和技術協議》的附函,日期為2020年2月24日,由本公司與Pvail InfoWorks,Inc.(通過引用本公司於2021年5月26日提交的F-1表格註冊聲明草案的附件10.7合併而成) | |
| 10.8% | | | 本公司與Prevail Partners LLC之間簽訂的認購協議,日期為2020年2月28日(參照本公司於2021年5月26日提交的F-1表格註冊聲明草案附件10.8) | |
| 10.9# | | | 公司與Next Level Consulters Inc.簽訂的諮詢協議,日期為2021年7月1日(參考公司於2021年7月21日提交的F-1表格註冊説明書修正案第1號附件10.10) | |
|
Exhibit
Number |
| |
Description
|
|
| 10.10% | | | 公司與佛羅裏達大學研究基金會公司之間簽訂的具有專有技術的標準獨家許可協議,自2014年6月23日起生效(通過參考公司於2021年8月12日提交的F-1表格註冊聲明的附件10.11合併而成) | |
| 10.11# | | | 公司與哈沃斯生物醫藥諮詢服務公司簽訂的諮詢協議,日期為2021年7月1日(參考公司於2021年7月21日提交的F-1表格註冊説明書修正案第1號附件10.12合併) | |
| 10.12% | | | 專利權購買協議,日期為2012年12月5日,由Richard Johnson博士、Takahiko Nakagawa博士和Revascor Inc.(通過引用2021年8月12日提交的公司F-1表格註冊聲明的附件10.13併入) | |
| 10.13 | | | 與大陸股票轉讓信託公司的認股權證代理協議格式(引用公司於2021年9月16日提交的F-1表格登記説明書第1號修正案附件10.14) | |
| 10.14** | | | 擔保代理協議格式 | |
| 10.15# | | | 公司與W.B.羅蘭茲有限公司簽訂的諮詢協議,日期為2018年3月1日(參考公司於2021年9月16日提交的F-1表格註冊説明書修正案第1號附件10.15合併) | |
| 10.16# | | | 公司、W.B.羅蘭茲有限公司和威廉·布魯斯·羅蘭茲之間簽訂並於2021年12月20日生效的諮詢服務協議(通過引用公司於2022年5月3日提交的Form 20-F年度報告的附件4.15合併而成) | |
| 10.17# | | | 股票期權計劃(以引用方式併入本公司於2021年11月23日提交的6-K表格附件99.2的附表B) | |
| 10.18% | | | 理查德·約翰遜博士、中川隆彥博士和公司於2014年5月26日生效的專利權購買協議(通過參考2022年5月3日提交的公司20-F表格年度報告的附件4.17併入) | |
| 10.19% | | | 公司與佛羅裏達大學研究基金會公司於2014年6月23日生效的股權協議(合併內容參考公司於2022年5月3日提交的Form 20-F年報附件4.18) | |
| 10.20% | | | 科羅拉多大學董事會與該公司於2021年5月27日簽署的贊助研究協議(通過參考2022年5月3日提交的公司年度報告Form 20-F的附件4.19合併而成) | |
| 10.21% | | | 本公司與商科學有限公司於2021年7月19日簽訂的綜合主服務協議(參照本公司於2022年5月3日提交的Form 20-F年報附件4.20合併) | |
| 10.22 | | | 公司與龍沙有限公司於2021年8月17日生效的開發和臨牀製造服務協議(參考公司於2022年5月3日提交的Form 20-F年報附件4.21合併) | |
| 10.23 | | | Altasciences Company Inc.(一家合同研究機構)與公司於2021年12月22日生效的全球主服務協議(通過引用附件4.22併入公司於2022年5月3日提交的Form 20-F年報) | |
| 10.24 | | | XORTX治療公司的建議書,日期為2022年2月21日,由公司和Covar PharmPharmticals Inc.(通過引用2022年5月3日提交的公司年度報告Form 20-F的附件4.23合併而成) | |
| 10.25 | | | XORTX治療公司的建議書,日期為2021年12月6日,由公司和Covar PharmPharmticals Inc.(通過引用2022年5月3日提交的公司年度報告Form 20-F的附件4.24合併而成) | |
|
Exhibit
Number |
| |
Description
|
|
| 10.26% | | | 公司與西班牙庫裏亞大學之間的建議書,日期為2022年3月29日(通過引用2022年5月3日提交的公司年度報告20-F表的附件4.25合併) | |
| 10.27# | | | 公司與Stephen Haworth之間的諮詢修訂協議,日期為2022年1月27日(通過引用2022年5月3日提交的公司年度報告Form 20-F的附件4.26併入) | |
| 10.28# | | | 公司與Amar Keshri之間的協議,日期為2021年11月1日(參考2022年5月3日提交的公司年度報告Form 20-F的附件4.27合併) | |
| 21.1 | | | 公司子公司(參照公司於2021年5月26日提交的F-1表格註冊説明書草案附件21.1註冊成立) | |
| 23.1** | | | 獨立註冊會計師事務所(Smythe LLP)同意 | |
| 23.2** | | | 經Fasken Martineau Dumoulin LLP同意(包含在附件5.1中) | |
| 23.3** | | | Troutman Pepper Hamilton Sanders LLP的同意(包含在附件5.2中)。 | |
| 24.1** | | | 授權書(包括在登記聲明的簽名頁上) | |
| 107** | | | Filing Fee Table | |
|
Signatures
|
| |
Title
|
| |
Date
|
|
|
Allen Davidoff
|
| |
總裁兼首席執行官和董事(首席執行官)
|
| |
|
|
|
Amar Keshri
|
| |
首席財務官(首席財務官和首席會計官)
|
| |
|
|
|
William Farley
|
| |
Director
|
| |
|
|
|
Anthony Giovinazzo
|
| |
Director
|
| |
|
|
|
Ian Klassen
|
| |
Director
|
| |
|
|
|
Jacqueline Le Saux
|
| |
Director
|
| |
|
|
|
Raymond Pratt
|
| |
Director
|
| |
|
|
|
Paul Van Damme
|
| |
Director
|
| |
|
|